Cited by 400Radiopharmaceutical Chemistry and ApplicationsLymphoma Diagnosis and TreatmentMonoclonal and Polyclonal Antibodies Research

The DOI matches its Crossref record.

Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma

Kaminski, M S, Zasadny, K R, Francis, I R, Fenner, M C, Ross, C W, Milik, A W, Estes, J, Tuck, M, Regan, D, Fisher, S, Glenn, S D, Wahl, R L·1996·Journal of Clinical Oncology

DOI 10.1200/jco.1996.14.7.1974

Open this paper in CoChat — free account

Abstract

PURPOSE: The CD20 B-lymphocyte surface antigen expressed by B-cell lymphomas is an attractive target for radioimmunotherapy, treatment using radiolabeled antibodies. We conducted a phase I dose-escalation trial to assess the toxicity, tumor targeting, and efficacy of nonmyeloablative doses of an anti-CD20 monoclonal antibody (anti-B1) labeled with iodine-131 (131I) in 34 patients with B-cell lymphoma who had failed chemotherapy. PATIENTS AND METHODS: Patients were first given tracelabeled doses of 131I-labeled anti-B1 (15 to 20 mg, 5 mCi) to assess radiolabeled antibody biodistribution, and then a radioimmunotherapeutic dose (15 to 20 mg) labeled with a quantity of 131I that would deliver a specified centigray dose of whole-body radiation predicted by the tracer dose. Whole-body radiation doses were escalated from 25 to 85 cGy in sequential groups of patients in 10-cGy increments. To evaluate if radiolabeled antibody biodistribution could be optimized, initial patients were given one or two additional tracer doses on successive weeks, each dose preceded by an infusion of 135 mg of unlabeled anti-B1 one week and 685 mg the next. The unlabeled antibody dose resulting in the most optimal tracer biodistribution was also given before the radioimmunotherapeutic dose. Later patients were given a single tracer dose and radioimmunotherapeutic dose preceded by infusion of 685 mg of unlabeled anti-B1. RESULTS: Treatment was well tolerated. Hematologic toxicity was dose-limiting, and 75 cGy was established as the maximally tolerated whole-body radiation dose. Twenty-eight patients received radioimmunotherapeutic doses of 34 to 161 mCi, resulting in complete remission in 14 patients and a partial response in eight. All 13 patients with low-grade lymphoma responded, and 10 achieved a complete remission. Six of eight patients with transformed lymphoma responded. Thirteen of 19 patients whose disease was resistant to their last course of chemotherapy and all patients with chemotherapy-sensitive disease responded. The median duration of complete remission exceeds 16.5 months. Six patients remain in complete remission 16 to 31 months after treatment. CONCLUSION: Nonmyeloablative radioimmunotherapy with 131I-anti-B1 is associated with a high rate of durable remissions in patients with B-cell lymphoma refractory to chemotherapy.

Integrity signals

Registry

Crossref · 10.1200/jco.1996.14.7.1974

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Sorted by citations

Items 201–300 of 400

Use of imaging-based dosimetry for personalising radiopharmaceutical therapy of cancer
Beauregard, J. (2022) · Cancer Imaging · doi:10.1186/s40644-022-00505-y · Cited by 22
“75 Gy to the wholebody was found to be the maximum tolerated dose [17].”
Background
Clinical Trial Design and Scoring of Radionuclide Therapy Endpoints: Normal Organ Toxicity and Tumor Response
Meredith, R. F. (2002) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/10849780252824109 · Cited by 18
Initial Experience with Tositumomab and I-131-Labeled Tositumomab for Treatment of Relapsed/Refractory Hodgkin Lymphoma
Jacene, H. A., Crandall, J. P., Kasamon, Y. L., Ambinder, R. F., Piantadosi, S., Serena, D., Kasecamp, W., & Wahl, R. L. (2016) · Molecular Imaging and Biology · doi:10.1007/s11307-016-1019-9 · Cited by 17
Self-citation
Development of 131I-tositumomab
Lewington, V. J. (2005) · Seminars in Oncology · doi:10.1053/j.seminoncol.2005.01.014 · Cited by 17
Radiation-induced apoptosis
Illidge, T. (1998) · Clinical Oncology · doi:10.1016/s0936-6555(98)80104-0 · Cited by 17
Phase I/II Trial of Anticarcinoembryonic Antigen Radioimmunotherapy, Gemcitabine, and Hepatic Arterial Infusion of Fluorodeoxyuridine Postresection of Liver Metastasis for Colorectal Carcinoma
Cahan, B. L., Leong, L., Wagman, L. D., et al. (2017) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2017.2223 · Cited by 17
High-dose therapy for follicular lymphoma.
Freedman, A. S., Friedberg, J. W., & Gribben, J. (2000) · PubMed · Cited by 17
Monoclonal antibody therapy for B cell non-Hodgkin’s lymphomas: emerging concepts of a tumour-targeted strategy
Buske, C., Feuring‐Buske, M., Unterhalt, M., & Hiddemann, W. (1999) · European Journal of Cancer · doi:10.1016/s0959-8049(98)00420-1 · Cited by 17
Advances in the use of monoclonal antibodies in cancer radiotherapy
Govindan, S. V., Goldenberg, D. M., Hansen, H. J., et al. (2000) · Pharmaceutical Science & Technology Today · doi:10.1016/s1461-5347(00)00241-8 · Cited by 17
TARGETED THERAPY FOR LYMPHOMA WITH PEPTIDES
Lam, K. S., & Zhao, Z. (1997) · Hematology/Oncology Clinics of North America · doi:10.1016/s0889-8588(05)70476-7 · Cited by 16
Immunotherapy with anti-CD20 compounds
von Schilling, C. (2003) · Seminars in Cancer Biology · doi:10.1016/s1044-579x(03)00018-x · Cited by 17
I-131 tositumomab
William, B. M., & Bierman, P. J. (2010) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2010.504707 · Cited by 16
“Grade 3 -- 4 myelosuppression was only observed in patients treated with TBD of 85 cGy [30,31].”
Background
Enhanced Targeting Specificity to Tumor Cells by Simultaneous Recognition of Two Antigens
de Boisferon, M. H., Raguin, O., Dussaillant, M., et al. (2000) · Bioconjugate Chemistry · doi:10.1021/bc9901090 · Cited by 16
Radioimmunotherapy in mantle cell lymphoma
Skarbnik, A. P. Z., & Smith, M. R. (2012) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2012.04.004 · Cited by 16
“Thus, as for rituximab, CD20, a transmembrane phosphoprotein expressed in more than 90% of B-cell NHL, as well as in mature B-cells and pre-B cells, but not in plasma cells or stem cells, presents an attractive target in lymphoma.”
BackgroundInfluential
A cell surface molecule, JL1; a specific target for diagnosis and treatment of leukemias
Park, W., Bae, Y., Dh, C., et al. (1998) · Leukemia · doi:10.1038/sj.leu.2401161 · Cited by 16
Monoclonal antibody therapy
Park, J. W., & Smolen, J. S. (2001) · Advances in protein chemistry · doi:10.1016/s0065-3233(01)56010-6 · Cited by 16
A review of tositumomab and I131tositumomab radioimmunotherapy for the treatment of follicular lymphoma
Davies, A. J. (2005) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.5.4.577 · Cited by 16
“The maximal tolerated whole-body dose was established as 75 cGy, limited by haematological toxicity [35].”
BackgroundMethod
Bi-Specific Antibodies in Cancer Therapy
Wang, H., Liu, Y., Wei, L., & Guo, Y. (2002) · Advances in experimental medicine and biology · doi:10.1007/0-306-46817-4_32 · Cited by 15
“, 1998), CD20 (Kaminski et al., 1996), CD37 (Ely et al.”
Synergistic interaction between anti-p185HER-2 ricin A chain immunotoxins and radionuclide conjugates for inhibiting growth of ovarian and breast cancer cells that overexpress HER-2.
Xu, F., Leadon, S. A., Yu, Y., et al. (2000) · PubMed · Cited by 15
Indolent B-cell non-Hodgkin's lymphomas.
Seng, J. E., & Peterson, B. A. (1997) · PubMed · Cited by 15
Prospects for future studies in head and neck cancer
van Dongen, G. A. M. S., & Snow, G. B. (1997) · European Journal of Surgical Oncology · doi:10.1016/s0748-7983(97)92789-x · Cited by 15
Clinical development of radioimmunotherapy for B-cell non-Hodgkin’s lymphoma
Meredith, R. F., & Knox, S. J. (2006) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2006.04.059 · Cited by 15
Antibody therapy of lymphoma
Bayne, M. C., & Illidge, T. (2001) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2.6.953 · Cited by 15
Advances in the systemic treatment of cancers in the elderly
Carbone, P. P. (2000) · Critical Reviews in Oncology/Hematology · doi:10.1016/s1040-8428(00)00049-4 · Cited by 15
Monoclonal antibodies and autologous stem cell transplantation for lymphoma
Flinn, I. W., & Lazarus, H. M. (2001) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1702857 · Cited by 15
High‐dose radioimmunotherapy combined with extracorporeal depletion in a syngeneic rat tumor model
Mårtensson, L., Nilsson, R., Ohlsson, T. G., et al. (2010) · Cancer · doi:10.1002/cncr.24791 · Cited by 14
Follicular lymphoma: a historical overview
van Besien, K., & Schouten, H. C. (2007) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190601059746 · Cited by 15
Dose-attenuated radioimmunotherapy with tositumomab and iodine 131 tositumomab in patients with recurrent non-Hodgkin's lymphoma (NHL) and extensive bone marrow involvement
Mones, J. V., Coleman, M., Kostakoğlu, L., et al. (2007) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190601059720 · Cited by 14
Immunohistochemical analysis of intratumoral heterogeneity of [131I]cG250 antibody uptake in primary renal cell carcinomas
Steffens, M. G., Oosterwijk, E., Zegwaart-Hagemeier, N. E. M., et al. (1998) · British Journal of Cancer · doi:10.1038/bjc.1998.656 · Cited by 14
Monoclonal Antibodies in the Treatment of Human B-Cell Malignancies
Link, B. K., & Weiner, G. J. (1998) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428199809059217 · Cited by 14
Anti-CD20 monoclonal antibodies as novel treatments for non-Hodgkin's lymphoma
White, C. A., Larocca, A., & Grillo-López, A. J. (1999) · Pharmaceutical Science & Technology Today · doi:10.1016/s1461-5347(99)00128-5 · Cited by 14
Radioimmunotherapy in patients with head and neck squamous cell carcinoma: Initial experience
Colnot, D. R., Quak, J. J., Roos, J. C., et al. (2001) · Head & Neck · doi:10.1002/hed.1078 · Cited by 14
Establishing an institutional model for the administration of tositumomab and iodine I 131 tositumomab
Hohenstein, M. A., AUGUSTINE, S., Rutar, F. J., & Vose, J. M. (2003) · Seminars in Oncology · doi:10.1016/s0093-7754(03)70056-6 · Cited by 14
Some Like It Hot!
Cheson, B. D. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.19.3908 · Cited by 15
Rituximab and other emerging monoclonal antibody therapies for lymphoma
Tobinai, K. (2002) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.7.2.289 · Cited by 13
Pharmacokinetics and Dosimetry of 111 In/ 188 Re-Labeled PEGylated Liposomal Drugs in Two Colon Carcinoma-Bearing Mouse Models
Lin, Y.-Y., Chang, C.-H., Li, J.-J., Stabin, M. G., Chang, Y., Chen, L., Lin, M.-H., Tseng, Y., Lin, W., Lee, T., et al. (2011) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2010.0906 · Cited by 13
Patient-Specific Radiation Dosimetry for Radionuclide Therapy of Liver Tumors With Intrahepatic Artery Rhenium-188 Lipiodol
ZANZONICO, P. B., & Divgi, C. R. (2008) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2007.10.005 · Cited by 13
Pretargeting using peptide nucleic acid
Rusckowski, M., Qu, T., Chang, F., & Hnatowich, D. J. (1997) · Cancer · doi:10.1002/(sici)1097-0142(19971215)80:12+ · Cited by 63
Self-citation
Combination of Chemotherapy and Monoclonal Antibodies for the Treatment of Lymphoma
Thiéblemont, C., & Coiffier, B. (2002) · International Journal of Hematology · doi:10.1007/bf02982804 · Cited by 12
131I–Tositumomab in Lymphoma
Cheung, M. C., MacEachern, J., Haynes, A. E., Meyer, R. M., & Imrie, K. (2009) · Current Oncology · doi:10.3747/co.v16i5.385 · Cited by 12
“…et al., 1998 9 Gopal et al., 2003 10 Press et al., 1995 11 Liu et al., 1998 9 Gopal et al., 2003 10 Kaminski et al., 2000 12 Kaminski et al., 1993 13 Kaminski et al., 1996 14 Wahl et al., 1998 15 Bennet et al., 2005 16 Press et al., 2000 17 Gopal et al., 2002 18 Vose et al., 2000 19 Kaminski et…”
Radioimmunotherapeutic strategies in autologous hematopoietic stem-cell transplantation for malignant lymphoma
Inwards, D. J., Cilley, J., & Winter, J. N. (2006) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2006.05.004 · Cited by 12
Radioimmunotherapy with Iodine-131 Tositumomab in Patients with Low-Grade Non-Hodgkin's B-Cell Lymphoma Does Not Induce Loss of Acquired Humoral Immunity against Common Antigens
Nordøy, T., Kolstad, A., Tuck, M. K., Aaberge, I. S., Husebekk, A., & Kaminski, M. S. (2001) · Clinical Immunology · doi:10.1006/clim.2001.5050 · Cited by 12
Self-citation
131 I-labelled Anti-CD22 MAb (LL2) in Patients with B-Cell Lymphomas Failing Chemotherapy
Lindén, O., Tennvall, J., Hindorf, C., et al. (2002) · Acta Oncologica · doi:10.1080/02841860260088854 · Cited by 12
Iodine-131 tositumomab (Bexxar) in a radiation oncology environment
Macklis, R. M. (2006) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2005.06.002 · Cited by 12
High-dose therapy and stem cell transplantation in follicular lymphoma
Friedberg, J. W., & Freedman, A. S. (1999) · Annals of Hematology · doi:10.1007/s002770050503 · Cited by 12
Monoclonal antibodies in lymphoid neoplasia: Principles for optimal combined therapy
Maloney, D. G. (2000) · Seminars in Hematology · doi:10.1016/s0037-1963(00)90056-8 · Cited by 12
Radionuclide Dosimetry and Radioimmunotherapy of Cancer
Meredith, R. F., Buchsbaum, D. J., & Knox, S. J. (2000) · CRC Press eBooks · doi:10.1201/b14002-6 · Cited by 12
Physics for practitioners: The use of radiolabeled monoclonal antibodies in B-Cell non-Hodgkin's lymphoma
Press, O. W. (2000) · Seminars in Hematology · doi:10.1016/s0037-1963(00)90054-4 · Cited by 12
Monoclonal Antibodies in Conditioning Regimens for Hematopoietic Cell Transplantation
Kharfan‐Dabaja, M. A., Nishihori, T., Otrock, Z. K., et al. (2013) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2013.04.016 · Cited by 11
“Several small phase 2 studies using high-dose RIT with 131I-T alone, mainly in patients with chemosensitive relapsed B cell NHL, demonstrated 4-year PFS of 40% and OS of 65% (Table 3) [46-48], with acceptable toxicities.”
Background
Dose Intensified Molecular Targeted Radiotherapy for Cancer—Lymphoma as a Paradigm
DeNardo, G. L., & DeNardo, S. J. (2010) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2009.10.005 · Cited by 11
Antibody Therapy of Lymphoma
Weiner, G. J., & Link, B. K. (2004) · Advances in pharmacology · doi:10.1016/s1054-3589(04)51010-4 · Cited by 11
THE POTENTIAL FOR IMMUNOCONJUGATES IN LYMPHOMA THERAPY
Liu, S. Y., & Press, O. W. (1997) · Hematology/Oncology Clinics of North America · doi:10.1016/s0889-8588(05)70475-5 · Cited by 11
Monoclonal Antibodies in Cancer Treatment
Alpaugh, K. R., & von Mehren, M. (1999) · BioDrugs · doi:10.2165/00063030-199912030-00004 · Cited by 10
Radioimmunotherapy of human glioma xenografts in nude mice by indium-111 labelled internalising monoclonal antibody
Saga, T., Sakahara, H., Nakamoto, Y., et al. (1999) · European Journal of Cancer · doi:10.1016/s0959-8049(99)00120-3 · Cited by 10
Characterization of human IgG antimouse antibody in patients with B-cell malignancies.
DeNardo, G. L., Mirick, G. R., Kroger, L. A., Bradt, B. M., Lamborn, K. R., & DeNardo, S. J. (2003) · PubMed · Cited by 10
Radioimmunotherapy in the π-BCL 1 B cell Lymphoma Model: Efficacy Depends on More Than Targeted Irradiation Alone
Illidge, T., Honeychurch, J., Vandersteen, A., et al. (2000) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2000.15.581 · Cited by 10
Radioimmunotherapy for Liver Micrometastases in Mice: Pharmacokinetics, Dose Estimation, and Long‐term Effect
Saga, T., Sakahara, H., Nakamoto, Y., et al. (1999) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.1999.tb00753.x · Cited by 10
Enhanced Efficacy of Radioimmunotherapy Combined with Systemic Chemotherapy and Local Hyperthermia in Xenograft Model
Kinuya, S., Yokoyama, K., Konishi, S., et al. (2000) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.2000.tb00983.x · Cited by 10
Development of Radioimmunotherapy for the Treatment of Non-Hodgkin’s Lymphoma
Multani, P. S. (2002) · International Journal of Hematology · doi:10.1007/bf02982805 · Cited by 10
Monoclonal antibodies in the treatment of indolent lymphomas
Coiffier, B. (2005) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2004.08.016 · Cited by 10
Immunotherapy for non-Hodgkin's lymphoma.
Vose, J. M. (2001) · PubMed · Cited by 10
Myelosuppression in patients treated with177Lutetium-lilotomab satetraxetan can be predicted with absorbed dose to the red marrow as the only variable
Blakkisrud, J., Løndalen, A. M., Dahle, J., et al. (2021) · Acta Oncologica · doi:10.1080/0284186x.2021.1959635 · Cited by 9
New strategies in radioimmunotherapy for lymphoma
Pandit-Taskar, N. D., Hamlin, P. A., Reyes, S., Larson, S. M., & Divgi, C. R. (2003) · Current Oncology Reports · doi:10.1007/s11912-003-0020-z · Cited by 9
Bio-effect model applied to 131I radioimmunotherapy of refractory non-Hodgkin’s lymphoma
Roberson, P. L., Amro, H., Wilderman, S. J., Avram, A. M., Kaminski, M. S., Schipper, M. J., & Dewaraja, Y. K. (2010) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-010-1699-3 · Cited by 9
“Patients received a tracer infusion (5 mCi) of (131)I-tositumomab followed in 7 or 8 days by a therapy infusion (∼100 mCi) of (131)I-tositumomab using equal quantities of protein, a 450 mg flood injection followed by 35 mg (131)I-tagged injection [3, 14].”
Self-citation
Molecular biological design of novel antineoplastic therapies
Vulfovich, M., & Saba, N. F. (2004) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.13.6.577 · Cited by 9
FDG PET/CT parameters and correlations with tumor-absorbed doses in a phase 1 trial of 177Lu-lilotomab satetraxetan for treatment of relapsed non-Hodgkin lymphoma
Løndalen, A. M., Blakkisrud, J., Revheim, M.-E. R., Madsbu, U. E., Dahle, J., Kolstad, A., & Stokke, C. (2020) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-020-05098-x · Cited by 9
Radioimmunotherapy in non-Hodgkin lymphoma
Chanan-Khan, A. A., & Czuczman, M. S. (2002) · Current Opinion in Oncology · doi:10.1097/00001622-200209000-00003 · Cited by 9
Aggressive lymphoma in the elderly
Lichtman, S. M. (2000) · Critical Reviews in Oncology/Hematology · doi:10.1016/s1040-8428(99)00061-x · Cited by 9
Combination Therapy for Non-Hodgkin’s Lymphoma: An Opportunity for Pharmaceutical Care in a Specialty Practice
Augustine, S. C., Norenberg, J. P., Colcher, D. M., Vose, J. M., Gobar, L. S., Dukat, V. J., Hohenstein, M. A., Rutar, F. J., Jacobson, D. A., & Tempero, M. A. (2002) · Journal of the American Pharmaceutical Association (1996) · doi:10.1331/108658002763538125 · Cited by 9
Advances in immunotherapy of hematologic malignancies: cellular and humoral approaches
Jurcic, J. G., Cathcart, K. N. S., Pinilla-Ibarz, J. A., et al. (2000) · Current Opinion in Hematology · doi:10.1097/00062752-200007000-00008 · Cited by 9
Radiolabeled Anti-Adenosine Triphosphate Synthase Monoclonal Antibody as a Theragnostic Agent Targeting Angiogenesis
Park, B.-N., Lee, S. J., Roh, J. H., Lee, K.-H., An, Y., & Yoon, J. (2017) · Molecular Imaging · doi:10.1177/1536012117737399 · Cited by 7
Personalized Dosimetry of 131 I-Rituximab Radioimmunotherapy of Non-Hodgkin Lymphoma Defined by Pharmacokinetics in Bone Marrow and Blood
Bouček, J., & Turner, J. (2013) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2013.1490 · Cited by 8
Effect of 67Cu-2IT-BAT-Lym-1 therapy on BCL-2 gene and protein expression in a lymphoma mouse model.
Kroger, L. A., DeNardo, S. J., DeNardo, G. L., et al. (1999) · PubMed · Cited by 8
Monoclonal Antibody Therapy with Autologous Peripheral Blood Stem Cell Transplantation for Non-Hodgkin's Lymphoma
Aksentijevich, I., & Flinn, I. W. (2002) · Cancer Control · doi:10.1177/107327480200900202 · Cited by 8
IgE and Its Role in Parasitic Helminth Infection
Cooper, P. J., & Nutman, T. B. (2002) · Lung biology in health and disease · doi:10.1201/b14035-20 · Cited by 8
Evaluation in a Mouse Model of a Thyroid-blocking Protocol for 131 I Antibody Therapy (Short Communication)
Zuckier, L. S., Li, Y., & Chang, C. (1998) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.1998.13.457 · Cited by 8
APPLICATION OF CELL ENGINEERING TECHNOLOGY TO THE TUMOUR IMMUNOTHERAPEUTIC DRUG: A REVIEW
Chen, Z., Xing, J., Bian, H., et al. (2001) · Cell Biology International · doi:10.1006/cbir.2001.0753 · Cited by 7
Biotherapy for lymphoma
McLaughlin, P. J. (2000) · Current Oncology Reports · doi:10.1007/s11912-000-0088-7 · Cited by 7
Comparison of Radiation Dose Estimation for Myeloablative Radioimmunotherapy for Relapsed or Recurrent Mantle Cell Lymphoma Using 131 I Tositumomab to That of Other Types of Non-Hodgkin's Lymphoma
Rajendran, J. G., Gopal, A. K., Durack, L. D., et al. (2004) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2004.19.738 · Cited by 7
Targeted radionuclide therapy of cancer
Pagel, J. M., Boerman, O. C., Breitz, H. B., & Meredith, R. F. (2009) · Springer eBooks · doi:10.1007/978-90-481-2289-9_13 · Cited by 8
Mantle Cell Lymphoma: New Treatments Targeted to the Biology
Bertoni, F., Ghielmini, M. E. G., Cavalli, F., et al. (2002) · Clinical Lymphoma · doi:10.3816/clm.2002.n.014 · Cited by 7
Radioimmunotherapy with 131 I-Rituximab: What We Know and What We Don't Know
Juweid, M. E. (2003) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/108497803322287565 · Cited by 7
Correlation of marrow dose estimates based on serial pretreatment radiopharmaceutical imaging and blood data with actual marrow toxicity in anti-CD20 yttrium-90 monoclonal antibody radioimmunotherapy of non-Hodgkinʼs B-cell lymphoma
Erwin, W. D., SPIES, S. M., KELLY, M. E., et al. (2001) · Nuclear Medicine Communications · doi:10.1097/00006231-200102000-00018 · Cited by 7
Non-Hodgkin's lymphoma: Follicle centre cell lymphoma: optimal use of therapeutic options
Rohatiner, A. Z. S. (2000) · Annals of Oncology · doi:10.1093/annonc/11.suppl_3.111 · Cited by 7
Optimal Indications of Radioimmunotherapy in Nuclear Medicine: A Mini-Review
Vahidfar, N., Ahmadzadehfar, H., Farzanefar, S., et al. (2024) · Current Radiopharmaceuticals · doi:10.2174/0118744710295825240308093429 · Cited by 6
New insights into the mechanisms of action of radioimmunotherapy in lymphoma
Иванов, А. В., Swann, R., & Illidge, T. (2008) · Journal of Pharmacy and Pharmacology · doi:10.1211/jpp.60.8.0006 · Cited by 6
“Kaminski and colleagues initially conducted a series of trials at the University of Michigan using 131I-tositumomab, for the treatment of relapsed follicular lymphoma (Kaminski et al 1993, 1996).”
Background
Targeted Radionuclide Therapy
Jurcic, J. G., Wong, J. Y. C., Knox, S. J., Wahl, D. R., Rosenblat, T. L., & Meredith, R. F. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-24098-7.00022-8 · Cited by 7
Immunotherapy: the last 25 years
Plunkett, T. A., & Miles, D. W. (1999) · Cancer Treatment Reviews · doi:10.1053/ctrv.1999.0135 · Cited by 6
Radioimmunotherapy in Non-Hodgkin's Lymphoma: Trials of Yttrium 90–Labeled Ibritumomab Tiuxetan and Beyond
Evens, A. M., & Gordon, L. I. (2004) · Clinical Lymphoma · doi:10.3816/clm.2004.s.003 · Cited by 6
Radioimmunotherapy: a brief overview
Ng, D. C. E. (2006) · Biomedical Imaging and Intervention Journal · doi:10.2349/biij.2.3.e23 · Cited by 6
Emerging concepts in the management of the malignant haematological disorders
Jønsson, V., Gemmell, C. G., & Wiik, A. S. (2000) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.1.4.713 · Cited by 6
Emerging Immunotherapies for Non-Hodgkin Lymphomas: The Tortoise Approaches the Finish Line
Press, O. W. (2000) · Annals of Internal Medicine · doi:10.7326/0003-4819-132-11-200006060-00012 · Cited by 6
“Studies using minimally toxic, nonmyeloablative doses of iodine-131–tositumomab (anti-CD20) (11) and yttrium-90–Y2B8 (12, 13) have demonstrated response rates of 67% to 80%, including complete remission rates of 27% to 40% in patients with relapsed lymphomas.”
Background
131I Tositumomab
Culy, C. R., & Lamb, H. M. (2000) · BioDrugs · doi:10.2165/00063030-200014030-00005 · Cited by 6
“Combination Therapy Dose-escalation studies show that 131I tositumomab produces better results at high doses;[8]”
BackgroundMethodInfluential
Radionuclides as conditioning before stem cell transplantation
Jurcic, J. G., & Scheinberg, D. A. (1999) · Current Opinion in Hematology · doi:10.1097/00062752-199911000-00003 · Cited by 6
Update on the rational use of tositumomab and iodine-131 tositumomab radioimmunotherapy for the treatment of non-Hodgkin’s lymphoma
Macklis, R. M., & Burdick, M. J. (2009) · OncoTargets and Therapy · doi:10.2147/ott.s4456 · Cited by 5
“Standard dosing is 75 cGy total body irradiation 24 with dose reductions to 65 cGy for platelet counts between 100,000/mL and 150,000/mL 19 and dose reductions to 45 cGy for patients with previous autologous stem cell transplant (ASCT).”
PROGRESS IN NUCLEAR MEDICINE IMAGING OF CANCERS
Wahl, R. L. (1998) · Primary Care Clinics in Office Practice · doi:10.1016/s0095-4543(05)70068-3 · Cited by 5
Self-citation
Radioinmunoterapia en los linfomas no Hodgkin: desarrollo histórico y estado actual
Emmanouilides, C. E. (2006) · Revista Española de Medicina Nuclear · doi:10.1157/13083351 · Cited by 5
Treatment advances in non-Hodgkin’s lymphoma
Tan, B. R., & Bartlett, N. L. (2000) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.1.3.451 · Cited by 5
Phase 2 Study of Iodine-131 Tositumomab Plus Chemotherapy in Patients With Previously Untreated Mantle-Cell Lymphoma
Zelenetz, A. D., Popplewell, L. L., Noy, A., et al. (2019) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2019.04.010 · Cited by 5
Clinical application of radioiodinated antibodies: where are we?
Oliveira, M. C., & Correia, J. D. G. (2022) · Clinical and Translational Imaging · doi:10.1007/s40336-021-00477-2 · Cited by 5

Authors: Kaminski, M. S., Zasadny, K. R., Francis, I. R., Fenner, M. C., Ross, C. W., Milik, A. W., Estes, J., Tuck, M., Regan, D., Fisher, S., Glenn, S. D., & Wahl, R. L.
Affiliations: University of Michigan (US)
ORCID: Kaminski, M S
Francis, I R
Tuck, M
Glenn, S D
Wahl, R L
Venue: Journal of Clinical Oncology
Publisher: American Society of Clinical Oncology (ASCO)
Published: 1996-07
Volume: 14
Issue: 7
Pages: 1974-1981
ISSN: 0732-183X (ISSN-L)
1527-7755
DOI: 10.1200/jco.1996.14.7.1974
OpenAlex: W1892026381
Cited by: 396
References: 0
Citations by year: 2024: 2 · 2023: 6 · 2022: 5 · 2021: 3 · 2020: 3 · 2019: 1 · 2018: 2 · 2017: 4 · 2016: 5 · 2015: 4 · 2014: 5 · 2013: 4 · 2012: 6
FWCI: 28.19
Type: journal article
Language: en
Open access: closed
Locations: Journal of Clinical Oncology (publishedVersion)
PubMed (publishedVersion)
Funders: National Institutes of Health (5r01ca056794-08, 5p01ca042768-03)
National Cancer Institute (R01-CA-56794, P0-1 CA42768)
National Center for Research Resources (M-01RR00042, M01RR000042)
Topics: Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiopharmaceutical Chemistry and Applications
Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
Keywords: iodine-131, anti-CD20 monoclonal antibody, radioimmunotherapy, B-cell lymphoma, treatment toxicity, hematologic toxicity, tumor targeting, tissue distribution, complete remission, relapsed/refractory lymphoma, indolent lymphoma, transformed lymphoma, chemotherapy-refractory disease
MeSH terms: Adult, Aged, Antibodies, Monoclonal, Dose-Response Relationship, Radiation, Female, Humans, Iodine Radioisotopes, Male, Middle Aged, Remission Induction, Lymphoma, B-Cell, Radioimmunotherapy, Antigens, CD20

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cited by

Related

Metadata

Record

About these checks